{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:35:37Z","timestamp":1792888537846,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Enterococcal<\/jats:italic>\n                    bloodstream infections (BSI) are associated with high morbidity and limited treatment options, particularly in resource-limited settings where access to standard agents may be constrained. Comparative effectiveness data directly informing the choice among available agents for both vancomycin-resistant (VRE) and ampicillin-resistant, vancomycin-susceptible (VSE)\n                    <jats:italic>enterococcal<\/jats:italic>\n                    bacteremia are specifically lacking in such settings, where regimen selection is frequently dictated by drug availability and cost rather than guideline preference. We conducted a retrospective cohort study across three hospitals of a single university health system (Dr. Ziauddin University, Karachi, Pakistan) including hospitalized adults (\u2265\u200918\u00a0years) with clinically significant\n                    <jats:italic>enterococcal<\/jats:italic>\n                    bacteremia (a positive blood culture together with clinical evidence of infection, as adjudicated by the treating physician) between January 1, 2010, and May 31, 2025. Only the first episode per patient was analyzed. VRE and VSE cohorts were compared for baseline characteristics and empiric therapy. Definitive monotherapy\u2014receipt of a single study agent active against the isolate, assigned within the prespecified 48- to 72-h window after index blood culture (time-zero), by which time organism identification and susceptibility results were generally available\u2014was assessed within the VRE and VSE cohorts. Because discharge alive is a competing event for in-hospital death, cumulative incidence functions (CIF) with Gray\u2019s test and an adjusted Fine\u2013Gray competing-risks model (adjusted for age, Charlson Comorbidity Index, qPitt score, septic shock, and definitive antibiotic exposure (vancomycin, teicoplanin, daptomycin, tigecycline)) were used. Of 925 screened patients, 501 met inclusion criteria (VSE\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009404; VRE\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200997). VRE bacteremia presented with greater acute severity (higher APACHE II) and was more frequently catheter-associated, while VSE more often had urinary and intra-abdominal sources (all\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). In definitive monotherapy analyses among VRE (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200967; tigecycline excluded, as it was used only as salvage therapy), 28-day mortality was numerically higher with teicoplanin (66.7%) but did not differ significantly across linezolid, teicoplanin, and daptomycin; CIF analysis similarly showed no difference in cumulative incidence of in-hospital death (Gray\u2019s\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.246). Tigecycline, used only as salvage therapy, was associated with higher 28-day mortality (80.0% vs 47.8%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003; Supplementary Table S1). In VSE monotherapy (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009404), teicoplanin exposure was associated with higher ICU admission and higher 28-day mortality, and CIF curves differed across vancomycin, teicoplanin, and linezolid (Gray\u2019s\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001); however, the linezolid-exposed group had sparse\/zero events for several endpoints, suggesting confounding by indication. In the adjusted Fine\u2013Gray model, higher qPitt score was independently associated with mortality (sHR 2.21, 95% CI 1.62\u20133.01;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Tigecycline (sHR 4.00, 95% CI 2.11\u20137.60;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and daptomycin exposure (sHR 3.11, 95% CI 1.37\u20137.07;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007) were associated with higher subdistribution hazard of death, whereas vancomycin exposure was associated with lower hazard (sHR 0.36, 95% CI 0.20\u20130.67;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001). In this multi-hospital, single-system cohort, VRE bacteremia was more severe and more often catheter-associated than VSE. When accounting for discharge as a competing event, mortality differences across definitive monotherapy groups were not significant in VRE, while VSE comparisons were influenced by treatment selection and sparse outcome counts in some groups. Severity (qPitt score) was a key independent predictor of mortality, and observed antibiotic\u2013mortality associations should be interpreted cautiously given confounding by indication.\n                  <\/jats:p>","DOI":"10.1007\/s00210-026-05701-2","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T07:30:04Z","timestamp":1783841404000},"page":"20945-20957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of linezolid, glycopeptides, and other regimens in ampicillin-resistant, vancomycin-susceptible and vancomycin-resistant enterococcal bacteremia in a resource-limited setting: stewardship implications"],"prefix":"10.1007","volume":"399","author":[{"given":"Yameena Noman","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubab","family":"Murtaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irshad","family":"Batool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azizullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imtiaz","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9828-4109","authenticated-orcid":false,"given":"Jamil","family":"Muqtadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameeullah","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"issue":"4","key":"5701_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrmicro2761","volume":"10","author":"CA Arias","year":"2012","unstructured":"Arias CA, Murray BE (2012) The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 10(4):266\u2013278","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"5701_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1186\/s12879-021-06328-9","volume":"21","author":"H Awadh","year":"2021","unstructured":"Awadh H, Chaftari AM, Khalil M, Fares J, Jiang Y, Deeba R et al (2021) Management of enterococcal central line-associated bloodstream infections in patients with cancer. BMC Infect Dis 21(1):643","journal-title":"BMC Infect Dis"},{"issue":"15","key":"5701_CR3","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","volume":"132","author":"LM Baddour","year":"2015","unstructured":"Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ et al (2015) Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation 132(15):1435\u20131486","journal-title":"Circulation"},{"issue":"2","key":"5701_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01289-13","volume":"58","author":"EP Balli","year":"2014","unstructured":"Balli EP, Venetis CA, Miyakis S (2014) Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 58(2):734\u2013739","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"5701_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1586\/14787210.2015.1001839","volume":"13","author":"KE Barber","year":"2015","unstructured":"Barber KE, King ST, Stover KR, Pogue JM (2015) Therapeutic options for vancomycin-resistant enterococcal bacteremia. Expert Rev Anti Infect Ther 13(3):363\u2013377","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"5701_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/cid\/civ444","volume":"61","author":"NS Britt","year":"2015","unstructured":"Britt NS, Potter EM, Patel N, Steed ME (2015) Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of Veterans Affairs patients. Clin Infect Dis 61(6):871\u2013878","journal-title":"Clin Infect Dis"},{"key":"5701_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf323","author":"L Bussini","year":"2025","unstructured":"Bussini L, Bavaro DF, Brunetta E, Carella F, Accornero S, Rosselli Del Turco E et al (2025) What is the impact of anti-enterococcal empirical therapy on survival of patients with enterococcal bloodstream infections? Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaf323","journal-title":"Clin Infect Dis"},{"issue":"6","key":"5701_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s15010-021-01717-3","volume":"49","author":"C Cattaneo","year":"2021","unstructured":"Cattaneo C, Rieg S, Schwarzer G, M\u00fcller MC, Bl\u00fcmel B, Kern WV (2021) Enterococcus faecalis bloodstream infection: does infectious disease specialist consultation make a difference? Infection 49(6):1289\u20131297","journal-title":"Infection"},{"issue":"4","key":"5701_CR9","doi-asserted-by":"publisher","first-page":"E181","DOI":"10.1111\/1469-0691.12132","volume":"19","author":"AL Cheah","year":"2013","unstructured":"Cheah AL, Spelman T, Liew D, Peel T, Howden BP, Spelman D et al (2013) Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect 19(4):E181\u2013E189","journal-title":"Clin Microbiol Infect"},{"issue":"57","key":"5701_CR10","first-page":"33","volume":"5","author":"Choice of antibacterial drugs","year":"2007","unstructured":"Choice of antibacterial drugs (2007) Treat Guidel Med Lett 5(57):33\u201350","journal-title":"Treat Guidel Med Lett"},{"issue":"3","key":"5701_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jmii.2011.11.005","volume":"45","author":"C-H Chou","year":"2012","unstructured":"Chou C-H, Lee N-Y, Lee H-C, Chang C-M, Lee C-C, Ko W-C (2012) Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan. J Microbiol Immunol Infect 45(3):221\u2013227","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"5701_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-014-0687-9","volume":"14","author":"Y-C Chuang","year":"2014","unstructured":"Chuang Y-C, Wang J-T, Lin H-Y, Chang S-C (2014) Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect Dis 14(1):1\u201310","journal-title":"BMC Infect Dis"},{"issue":"10","key":"5701_CR13","doi-asserted-by":"publisher","first-page":"890.e1","DOI":"10.1016\/j.cmi.2016.07.018","volume":"22","author":"Y-C Chuang","year":"2016","unstructured":"Chuang Y-C, Lin H-Y, Chen P-Y, Lin C-Y, Wang J-T, Chang S-C (2016) Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose. Clin Microbiol Infect 22(10):890.e1","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"5701_CR14","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1093\/jac\/dkaf242","volume":"80","author":"M Del Monte","year":"2025","unstructured":"Del Monte M, Kaleci S, Chester J, Zerbato V, Remitti M, Tili A et al (2025) Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study. J Antimicrob Chemother 80(9):2466\u20132473","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"5701_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ijantimicag.2019.08.018","volume":"54","author":"D Echeverria-Esnal","year":"2019","unstructured":"Echeverria-Esnal D, Sorli L, Prim N, Conde-Est\u00e9vez D, Mateu-De Antonio J, Martin-Ontiyuelo C et al (2019) Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score matched comparative study. Int J Antimicrob Agents 54(5):572\u20138","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"5701_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1473-3099(13)70324-4","volume":"14","author":"N Field","year":"2014","unstructured":"Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR et al (2014) Strengthening the reporting of molecular epidemiology for infectious diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis 14(4):341\u2013352","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"5701_CR17","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/INF.0000000000001919","volume":"37","author":"M Furuichi","year":"2018","unstructured":"Furuichi M, Furuichi M, Horikoshi Y, Miyairi I (2018) Infectious diseases consultation improves treatment and decreases mortality by enterococcal bacteremia in children. Pediatr Infect Dis J 37(9):856\u201360","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"5701_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0195-6701(94)90125-2","volume":"27","author":"J Gray","year":"1994","unstructured":"Gray J, Marsh PJ, Stewart D, Pedler SJ (1994) Enterococcal bacteraemia: a prospective study of 125 episodes. J Hosp Infect 27(3):179\u2013186","journal-title":"J Hosp Infect"},{"issue":"4","key":"5701_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4103\/0971-5916.159309","volume":"141","author":"V Gupta","year":"2015","unstructured":"Gupta V, Singla N, Behl P, Sahoo T, Chander J (2015) Antimicrobial susceptibility pattern of vancomycin resistant enterococci to newer antimicrobial agents. Indian J Med Res 141(4):483\u2013486","journal-title":"Indian J Med Res"},{"key":"5701_CR20","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s164515","author":"SMR Hashemian","year":"2018","unstructured":"Hashemian SMR, Farhadi T, Ganjparvar M (2018) Linezolid: a review of its properties, function, and use in critical care. Drug des Devel Ther. https:\/\/doi.org\/10.2147\/dddt.s164515","journal-title":"Drug des Devel Ther"},{"issue":"1","key":"5701_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkx349","volume":"73","author":"M Heidary","year":"2018","unstructured":"Heidary M, Khosravi AD, Khoshnood S, Nasiri MJ, Soleimani S, Goudarzi M (2018) Daptomycin. J Antimicrob Chemother 73(1):1\u201311","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"5701_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12874-018-0490-1","volume":"18","author":"M H\u00f6fler","year":"2018","unstructured":"H\u00f6fler M, Venz J, Trautmann S, Miller R (2018) Writing a discussion section: how to integrate substantive and statistical expertise. BMC Med Res Methodol 18(1):34","journal-title":"BMC Med Res Methodol"},{"key":"5701_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2025.08.005","author":"LE Hwang","year":"2025","unstructured":"Hwang LE, Yang JL, Lin CY, Huang SH, Chuang YC, Wang JT et al (2025) High-dose daptomycin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bloodstream infections: role of pharmacodynamic target attainment. J Microbiol Immunol Infect. https:\/\/doi.org\/10.1016\/j.jmii.2025.08.005","journal-title":"J Microbiol Immunol Infect"},{"issue":"9","key":"5701_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01067-25","volume":"13","author":"Y Jin","year":"2025","unstructured":"Jin Y, Yi Z, Hu Y, Huang M (2025) Epidemiology, clinical characteristics, and outcome of enterococcal bloodstream infections in critically ill patients in China: a single-center retrospective 10-year analysis. Microbiol Spectr 13(9):e0106725","journal-title":"Microbiol Spectr"},{"key":"5701_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081477","volume":"8","author":"M Johansen","year":"2013","unstructured":"Johansen M, Jensen JU, Bestle M, Hein L, Lauritsen A, Tousi H et al (2013) The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trial. PLoS ONE 8:e81477","journal-title":"PLoS ONE"},{"issue":"1s","key":"5701_CR26","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.chest.2019.10.064","volume":"158","author":"MW Kattan","year":"2020","unstructured":"Kattan MW, Vickers AJ (2020) Statistical analysis and reporting guidelines for CHEST. Chest 158(1s):S3-s11","journal-title":"Chest"},{"issue":"1","key":"5701_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1128\/AAC.47.1.216-222.2003","volume":"47","author":"A Lefort","year":"2003","unstructured":"Lefort A, Lafaurie M, Massias L, Petegnief Y, Saleh-Mghir A, Muller-Serieys C et al (2003) Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 47(1):216\u2013222","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"5701_CR28","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","volume":"367","author":"RJ Little","year":"2012","unstructured":"Little RJ, D\u2019Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT et al (2012) The prevention and treatment of missing data in clinical trials. N Engl J Med 367(14):1355\u20131360","journal-title":"N Engl J Med"},{"issue":"12","key":"5701_CR29","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S1473-3099(19)30405-0","volume":"19","author":"C Mejia-Chew","year":"2019","unstructured":"Mejia-Chew C, O\u2019Halloran JA, Olsen MA, Stwalley D, Kronen R, Lin C et al (2019) Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study. Lancet Infect Dis 19(12):1336\u20131344","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"5701_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/599376","volume":"49","author":"LA Mermel","year":"2009","unstructured":"Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O\u2019Grady NP et al (2009) Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 49(1):1\u201345","journal-title":"Clin Infect Dis"},{"issue":"11","key":"5701_CR31","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1128\/AAC.44.11.3022-3027.2000","volume":"44","author":"TM Murphy","year":"2000","unstructured":"Murphy TM, Deitz JM, Petersen PJ, Mikels SM, Weiss WJ (2000) Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 44(11):3022\u20133027","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5701_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1128\/CMR.3.1.46","volume":"3","author":"BE Murray","year":"1990","unstructured":"Murray BE (1990) The life and times of the Enterococcus. Clin Microbiol Rev 3(1):46\u201365","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"5701_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/clinids\/20.2.296","volume":"20","author":"GA Noskin","year":"1995","unstructured":"Noskin GA, Peterson LR, Warren JR (1995) Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 20(2):296\u2013301","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5701_CR34","doi-asserted-by":"publisher","first-page":"e2249353","DOI":"10.1001\/jamanetworkopen.2022.49353","volume":"6","author":"T Ohnuma","year":"2023","unstructured":"Ohnuma T, Chihara S, Costin B, Treggiari MM, Bartz RR, Raghunathan K, Krishnamoorthy V (2023) Association of appropriate empirical antimicrobial therapy with in-hospital mortality in patients with bloodstream infections in the US. JAMA Netw Open 6(1):e2249353","journal-title":"JAMA Netw Open"},{"issue":"9","key":"5701_CR35","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1093\/jac\/dkaf225","volume":"80","author":"TH Ou","year":"2025","unstructured":"Ou TH, Yang JL, Lin CY, Huang SH, Chuang YC, Wang JT et al (2025) Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection. J Antimicrob Chemother 80(9):2408\u20132416","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"5701_CR36","first-page":"332","volume":"10","author":"M Pereira","year":"2017","unstructured":"Pereira M, Rodrigues N, Godinho I, Gameiro J, Neves M, Gouveia J et al (2017) Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the \u2018risk, injury, failure, loss of kidney function, end-stage kidney disease\u2019 (RIFLE), acute kidney injury network (AKIN) and kidney disease: improving global outcomes (KDIGO) classifications. Clin Kidney J 10(3):332\u2013340","journal-title":"Clin Kidney J"},{"issue":"4","key":"5701_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.diagmicrobio.2010.03.009","volume":"67","author":"SD Putnam","year":"2010","unstructured":"Putnam SD, Sader HS, Moet GJ, Mendes RE, Jones RN (2010) Worldwide summary of telavancin spectrum and potency against gram-positive pathogens: 2007 to 2008 surveillance results. Diagn Microbiol Infect Dis 67(4):359\u2013368","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"5701_CR38","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1089\/mdr.2020.0171","volume":"27","author":"N Riccardi","year":"2021","unstructured":"Riccardi N, Monticelli J, Antonello RM, Di Lallo G, Frezza D, Luzzati R, Di Bella S (2021) Therapeutic options for infections due to vanB genotype vancomycin-resistant Enterococci. Microb Drug Resist 27(4):536\u201345","journal-title":"Microb Drug Resist"},{"issue":"3","key":"5701_CR39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.cmi.2020.10.029","volume":"27","author":"E Rosselli Del Turco","year":"2021","unstructured":"Rosselli Del Turco E, Bartoletti M, Dahl A, Cervera C, Peric\u00e0s JM (2021) How do I manage a patient with enterococcal bacteraemia? Clin Microbiol Infect 27(3):364\u201371","journal-title":"Clin Microbiol Infect"},{"key":"5701_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911925","author":"A Russo","year":"2022","unstructured":"Russo A, Picciarella A, Russo R, d\u2019Ettorre G, Ceccarelli G (2022) Time to effective therapy is an important determinant of survival in bloodstream infections caused by vancomycin-resistant Enterococcus spp. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms231911925","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5701_CR41","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jac\/dkaf055","volume":"80","author":"F Serapide","year":"2025","unstructured":"Serapide F, Serraino R, Spadafora L, Bernardi M, Brucci G, Cattardico G et al (2025) Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant enterococci: a multicentre clinical experience. J Antimicrob Chemother 80(5):1241\u20131247","journal-title":"J Antimicrob Chemother"},{"key":"5701_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JA Sterne","year":"2009","unstructured":"Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG et al (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338:b2393","journal-title":"BMJ"},{"issue":"4","key":"5701_CR43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167(4):492\u2013499","journal-title":"Am J Epidemiol"},{"issue":"8","key":"5701_CR44","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.cmi.2023.03.009","volume":"29","author":"J Tholany","year":"2023","unstructured":"Tholany J, Suzuki H, Livorsi DJ, Perencevich EN, Goto M (2023) The association of infectious diseases consultation and 30-day mortality rates among veterans with enterococcal bacteraemia: a propensity score-matched retrospective cohort study. Clin Microbiol Infect 29(8):1039\u20131044","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"5701_CR45","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jhm.994","volume":"7","author":"JD Twilla","year":"2012","unstructured":"Twilla JD, Finch CK, Usery JB, Gelfand MS, Hudson JQ, Broyles JE (2012) Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. J Hosp Med 7(3):243\u2013248","journal-title":"J Hosp Med"},{"issue":"3","key":"5701_CR46","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/cid\/ciac727","volume":"76","author":"J Van Heuverswyn","year":"2023","unstructured":"Van Heuverswyn J, Valik JK, van der Werff SD, Hedberg P, Giske C, Naucl\u00e9r P (2023) Association between time to appropriate antimicrobial treatment and 30-day mortality in patients with bloodstream infections: a retrospective cohort study. Clin Infect Dis 76(3):469\u201378","journal-title":"Clin Infect Dis"},{"issue":"7","key":"5701_CR47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.7326\/0003-4819-135-7-200110020-00007","volume":"135","author":"EN Vergis","year":"2001","unstructured":"Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK et al (2001) Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med 135(7):484\u2013492","journal-title":"Ann Intern Med"},{"issue":"10","key":"5701_CR48","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1128\/AAC.00210-06","volume":"50","author":"KB Waites","year":"2006","unstructured":"Waites KB, Duffy LB, Dowzicky MJ (2006) Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 50(10):3479\u20133484","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"5701_CR49","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1517\/14656560902811811","volume":"10","author":"J-L Wang","year":"2009","unstructured":"Wang J-L, Hsueh P-R (2009) Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother 10(5):785\u2013796","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"5701_CR50","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00277-019-03607-z","volume":"98","author":"S Weber","year":"2019","unstructured":"Weber S, Hogardt M, Reinheimer C, Wichelhaus TA, Kempf VAJ, Kessel J et al (2019) Bloodstream infections with vancomycin-resistant enterococci are associated with a decreased survival in patients with hematological diseases. Ann Hematol 98(3):763\u2013773","journal-title":"Ann Hematol"},{"issue":"10","key":"5701_CR51","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1128\/AAC.00714-13","volume":"57","author":"DW Whang","year":"2013","unstructured":"Whang DW, Miller LG, Partain NM, McKinnell JA (2013) Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother 57(10):5013\u20135018","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"5701_CR52","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jmii.2017.08.025","volume":"51","author":"J-J Ye","year":"2018","unstructured":"Ye J-J, Shie S-S, Cheng C-W, Yang J-H, Huang P-Y, Wu T-S et al (2018) Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia. J Microbiol Immunol Infect 51(6):705\u2013716","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"5701_CR53","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/s15010-025-02561-5","volume":"53","author":"V Zimmermann","year":"2025","unstructured":"Zimmermann V, Fourr\u00e9 N, Senn L, Guery B, Papadimitriou-Olivgeris M (2025) Predictors of mortality of enterococcal bacteraemia and the role of source control interventions; a retrospective cohort study. Infection 53(5):2149\u20132158","journal-title":"Infection"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05701-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05701-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05701-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:02:10Z","timestamp":1792886530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05701-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":53,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5701"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05701-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All study procedures were conducted in accordance with the Declaration of Helsinki and were approved by the Dr. Ziauddin University Ethical Review Committee on April 13, 2025. The committee also waived the requirement for written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}